Ticker
VYNECompany Name
VYNE THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQDate | Cash and Equivalents | Cash Ratio | Current Liabilities |
---|---|---|---|
6/30/2025 | $ 22.05M | 3.78 | $ 5.84M |
3/31/2025 | $ 28.21M | 2.3 | $ 12.29M |
12/31/2024 | $ 19.93M | 1.34 | $ 14.82M |
9/30/2024 | $ 16.32M | 1.29 | $ 12.66M |
6/30/2024 | $ 29.66M | 2.52 | $ 11.75M |
3/31/2024 | $ 19.12M | 2.76 | $ 6.93M |
12/31/2023 | $ 30.67M | 4.07 | $ 7.54M |
9/30/2023 | $ 15.5M | 2.4 | $ 6.45M |
6/30/2023 | $ 20.7M | 3.25 | $ 6.37M |
3/31/2023 | $ 30.28M | 4.03 | $ 7.52M |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
CashnEq / LiabilitesC
(=) Cash Ratio
Cash Ratio for VYNE THERAPEUTICS INC is calculated as follows: CashnEq [ $ 73.81M ] / LiabilitesC [ $ 23.19M ]
(=) Cash Ratio [ 3.18 ]
Minimum
Sep 30, 2024
Maximum
Jun 30, 2022
Average
Median
filtered constituents | 3.13K |
---|---|
min | 0 |
max | 2.69 |
average | 0.62 |
median | 0.39 |
std | 0.63 |